MIMEDX GROUP INC (MDXG) Fundamental Analysis & Valuation
NASDAQ:MDXG • US6024961012
Current stock price
3.95 USD
+0.09 (+2.33%)
At close:
3.9285 USD
-0.02 (-0.54%)
After Hours:
This MDXG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MDXG Profitability Analysis
1.1 Basic Checks
- MDXG had positive earnings in the past year.
- In the past year MDXG had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
- In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
- MDXG's Return On Assets of 14.18% is amongst the best of the industry. MDXG outperforms 94.78% of its industry peers.
- MDXG has a better Return On Equity (18.94%) than 95.36% of its industry peers.
- MDXG has a better Return On Invested Capital (16.82%) than 96.52% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MDXG is significantly below the industry average of 27.17%.
- The 3 year average ROIC (16.63%) for MDXG is below the current ROIC(16.82%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.18% | ||
| ROE | 18.94% | ||
| ROIC | 16.82% |
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of MDXG (11.60%) is better than 91.68% of its industry peers.
- MDXG has a better Operating Margin (15.26%) than 92.26% of its industry peers.
- MDXG's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 82.56%, MDXG belongs to the top of the industry, outperforming 85.49% of the companies in the same industry.
- MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.26% | ||
| PM (TTM) | 11.6% | ||
| GM | 82.56% |
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
2. MDXG Health Analysis
2.1 Basic Checks
- MDXG has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, MDXG has more shares outstanding
- Compared to 5 years ago, MDXG has more shares outstanding
- Compared to 1 year ago, MDXG has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 6.41 indicates that MDXG is not in any danger for bankruptcy at the moment.
- MDXG's Altman-Z score of 6.41 is fine compared to the rest of the industry. MDXG outperforms 77.56% of its industry peers.
- MDXG has a debt to FCF ratio of 0.25. This is a very positive value and a sign of high solvency as it would only need 0.25 years to pay back of all of its debts.
- MDXG has a better Debt to FCF ratio (0.25) than 95.55% of its industry peers.
- A Debt/Equity ratio of 0.06 indicates that MDXG is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.06, MDXG perfoms like the industry average, outperforming 40.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.25 | ||
| Altman-Z | 6.41 |
ROIC/WACC1.82
WACC9.26%
2.3 Liquidity
- MDXG has a Current Ratio of 4.32. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of MDXG (4.32) is comparable to the rest of the industry.
- MDXG has a Quick Ratio of 3.92. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.92, MDXG is in line with its industry, outperforming 49.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.32 | ||
| Quick Ratio | 3.92 |
3. MDXG Growth Analysis
3.1 Past
- MDXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.38%, which is quite impressive.
- The Revenue has grown by 19.99% in the past year. This is quite good.
- MDXG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.02% yearly.
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%
3.2 Future
- MDXG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.82% yearly.
- Based on estimates for the next years, MDXG will show a small growth in Revenue. The Revenue will grow by 4.92% on average per year.
EPS Next Y-71.81%
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue Next Year-15.29%
Revenue Next 2Y-2.15%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. MDXG Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 9.63, the valuation of MDXG can be described as reasonable.
- 96.71% of the companies in the same industry are more expensive than MDXG, based on the Price/Earnings ratio.
- Compared to an average S&P500 Price/Earnings ratio of 25.35, MDXG is valued rather cheaply.
- The Price/Forward Earnings ratio is 34.17, which means the current valuation is very expensive for MDXG.
- Based on the Price/Forward Earnings ratio, MDXG is valued cheaply inside the industry as 91.49% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 22.61, MDXG is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.63 | ||
| Fwd PE | 34.17 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaply inside the industry as 98.07% of the companies are valued more expensively.
- 97.68% of the companies in the same industry are more expensive than MDXG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.04 | ||
| EV/EBITDA | 5.4 |
4.3 Compensation for Growth
- MDXG has a very decent profitability rating, which may justify a higher PE ratio.
- MDXG's earnings are expected to decrease with -7.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
5. MDXG Dividend Analysis
5.1 Amount
- MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MDXG Fundamentals: All Metrics, Ratios and Statistics
3.95
+0.09 (+2.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2026-02-25/amc
Earnings (Next)04-28 2026-04-28
Inst Owners73.14%
Inst Owner Change0.19%
Ins Owners1.74%
Ins Owner Change1.43%
Market Cap586.85M
Revenue(TTM)418.63M
Net Income(TTM)48.58M
Analysts81.67
Price Target9.86 (149.62%)
Short Float %4.26%
Short Ratio6.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.4%
Min EPS beat(2)16.71%
Max EPS beat(2)110.08%
EPS beat(4)4
Avg EPS beat(4)53.83%
Min EPS beat(4)6.95%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)37.48%
EPS beat(12)11
Avg EPS beat(12)67.57%
EPS beat(16)12
Avg EPS beat(16)46.59%
Revenue beat(2)2
Avg Revenue beat(2)13.43%
Min Revenue beat(2)8.43%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)8.47%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)4.52%
Revenue beat(12)10
Avg Revenue beat(12)4.59%
Revenue beat(16)12
Avg Revenue beat(16)3.74%
PT rev (1m)-7.05%
PT rev (3m)-20.76%
EPS NQ rev (1m)-180%
EPS NQ rev (3m)-180%
EPS NY rev (1m)3.03%
EPS NY rev (3m)-53.74%
Revenue NQ rev (1m)-27.28%
Revenue NQ rev (3m)-27.28%
Revenue NY rev (1m)-12.9%
Revenue NY rev (3m)-17.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.63 | ||
| Fwd PE | 34.17 | ||
| P/S | 1.4 | ||
| P/FCF | 8.04 | ||
| P/OCF | 7.93 | ||
| P/B | 2.29 | ||
| P/tB | 2.63 | ||
| EV/EBITDA | 5.4 |
EPS(TTM)0.41
EY10.38%
EPS(NY)0.12
Fwd EY2.93%
FCF(TTM)0.49
FCFY12.43%
OCF(TTM)0.5
OCFY12.61%
SpS2.82
BVpS1.73
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.18% | ||
| ROE | 18.94% | ||
| ROCE | 22.95% | ||
| ROIC | 16.82% | ||
| ROICexc | 41.72% | ||
| ROICexgc | 59.54% | ||
| OM | 15.26% | ||
| PM (TTM) | 11.6% | ||
| GM | 82.56% | ||
| FCFM | 17.43% |
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
ROICexc(3y)34.07%
ROICexc(5y)N/A
ROICexgc(3y)46.74%
ROICexgc(5y)N/A
ROCE(3y)22.68%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y2.46%
ROICexc growth 3YN/A
ROICexc growth 5Y12.11%
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.25 | ||
| Debt/EBITDA | 0.21 | ||
| Cap/Depr | 6.94% | ||
| Cap/Sales | 0.25% | ||
| Interest Coverage | 51.27 | ||
| Cash Conversion | 93.95% | ||
| Profit Quality | 150.21% | ||
| Current Ratio | 4.32 | ||
| Quick Ratio | 3.92 | ||
| Altman-Z | 6.41 |
F-Score5
WACC9.26%
ROIC/WACC1.82
Cap/Depr(3y)32.56%
Cap/Depr(5y)46.17%
Cap/Sales(3y)0.47%
Cap/Sales(5y)0.75%
Profit Quality(3y)118.38%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-71.81%
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%
Revenue Next Year-15.29%
Revenue Next 2Y-2.15%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%
EBIT growth 1Y26.23%
EBIT growth 3YN/A
EBIT growth 5Y33.44%
EBIT Next Year-18.28%
EBIT Next 3Y13.89%
EBIT Next 5Y12.12%
FCF growth 1Y13.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.79%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
Can you provide the valuation status for MIMEDX GROUP INC?
ChartMill assigns a valuation rating of 6 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Fairly Valued.
How profitable is MIMEDX GROUP INC (MDXG) stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 7 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 9.63 and the Price/Book (PB) ratio is 2.29.
Can you provide the expected EPS growth for MDXG stock?
The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to decline by -71.81% in the next year.